Literature DB >> 16219645

Low bone density and low serum levels of soluble RANK ligand are associated with severe arterial calcification in patients with Takayasu arteritis.

M C Bezerra1, G D Calomeni, V F Caparbo, E S Gebrim, M S Rocha, R M R Pereira.   

Abstract

OBJECTIVE: Takayasu arteritis (TA) is a chronic inflammatory disorder affecting the aorta and its branches. Vascular calcification has been described in 29-54% of cases of TA, although its aetiology remains unknown. Recently the osteoprotegerin/RANKL/RANK system has emerged as an important contributing factor to atherogenesis and osteogenesis. Our aim is to investigate the association between vascular calcification, bone mineral density (BMD) and the osteoprotegerin/RANK/RANKL system in TA.
METHODS: Thirty pre-menopausal female TA patients and 30 age- and sex-matched controls were studied. BMD was measured by dual X-ray absorptiometry. Arterial calcification in TA patients was analysed by computed tomography in thoracic and abdominal sites. Serum levels of osteoprotegerin and soluble receptor activator of nuclear factor kappaB ligand (sRANKL) were quantified by enzyme-linked immunosorbent assay.
RESULTS: Patients with severe arterial calcification showed lower BMD values than controls in lumbar spine (0.965 +/- 0.055 vs 1.126 +/- 0.153 g/cm2, P = 0.009) and total body (0.993 +/- 0.065 vs 1.085 +/- 0.082 g/cm2, P = 0.019). In contrast, TA patients without calcification presented BMD values similar to controls (P > 0.05). Interestingly, lower serum levels of sRANKL (1.89 +/- 2.35 vs 2.80 +/- 2.23 pg/ml, P = 0.031) and a longer disease duration (12.20 +/- 6.61 vs 3.56 +/- 5.33 yr, P = 0.004) were observed in TA patients with severe calcification compared with patients without calcification.
CONCLUSIONS: Severe arterial calcification in TA is associated with low values of BMD and sRANKL, reinforcing the possible link between bone and vascular disease.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16219645     DOI: 10.1093/rheumatology/kei045

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  6 in total

1.  Development of outcome measures for large-vessel vasculitis for use in clinical trials: opportunities, challenges, and research agenda.

Authors:  Haner Direskeneli; Sibel Z Aydin; Tanaz A Kermani; Eric L Matteson; Maarten Boers; Karen Herlyn; Raashid A Luqmani; Tuhina Neogi; Philip Seo; Ravi Suppiah; Gunnar Tomasson; Peter A Merkel
Journal:  J Rheumatol       Date:  2011-07       Impact factor: 4.666

2.  Vascular surgery: the main risk factor for mortality in 146 Takayasu arteritis patients.

Authors:  Nilton Salles Rosa Neto; Samuel Katsuyuki Shinjo; Maurício Levy-Neto; Rosa Maria Rodrigues Pereira
Journal:  Rheumatol Int       Date:  2017-02-21       Impact factor: 2.631

Review 3.  Serum biomarkers for arterial calcification in humans: A systematic review.

Authors:  Nienke M S Golüke; Marit A Schoffelmeer; Annemarieke De Jonghe; Mariëlle H Emmelot-Vonk; Pim A De Jong; Huiberdina L Koek
Journal:  Bone Rep       Date:  2022-06-18

4.  High frequency of lipoprotein risk levels for cardiovascular disease in Takayasu arteritis.

Authors:  Jozélio Freire de Carvalho; Eloísa Bonfá; Mailze C Bezerra; Rosa Maria Rodrigues Pereira
Journal:  Clin Rheumatol       Date:  2009-03-13       Impact factor: 2.980

5.  Abnormal molecular response to Takayasu arteritis causing extensive large-vessel calcification.

Authors:  Brandon T Garland; Manfred Boehm; Peter C Grayson; Cynthia St Hilaire; Alessandra Brofferio; Benjamin W Starnes
Journal:  J Vasc Surg Cases Innov Tech       Date:  2016-12

6.  Decreased level of soluble receptor activator of nuclear factor-κβ ligand (sRANKL) in overweight and obese children.

Authors:  Michał Erazmus; Małgorzata Rumińska; Ewelina Witkowska-Sędek; Anna M Kucharska; Anna Stelmaszczyk-Emmel; Anna Majcher; Beata Pyrżak
Journal:  Front Endocrinol (Lausanne)       Date:  2022-08-19       Impact factor: 6.055

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.